Capricor Therapeutics reported second quarter 2026 financial results on August 13, 2026. The company posted a net loss of approximately $40.7 million, or $0.70 per share, compared to a $25.9 million loss in the prior year period. Total operating expenses rose to $42.9 million from $27.7 million, driven by increased research and development costs. Cash, cash equivalents, and marketable securities stood at approximately $238 million as of June 30, 2026. The filing provided a corporate update noting that the FDA Advisory Committee voted 3 to 9 against Deramiocel for cardiomyopathy in Duchenne muscular dystrophy, though it was not asked to vote on the primary upper limb endpoint which achieved statistical significance (p=0.029). The company also disclosed an FDA BIMO inspection Form 483 and a contractual dispute with NS Pharma pending arbitration. Capricor Therapeutics is a biotechnology company developing cell and exosome-based therapeutics for rare diseases.
